Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
Diagnostischer Wert von Serum-p-tau217 bei Alzheimer-Krankheit: gleichwertig zu Plasma in Konzentrationen und klinischem Nutzen?
Clinical Chemistry · 03.02.2026 · 72 (2) · 303-315
DOI: 10.1093/clinchem/hvaf162 ↗Auf einen Blick
Bei 100 Personen im Alzheimer-Kontinuum korrelierten Serum- und Plasma-p-tau217 bei den meisten Assays stark. Die absoluten Werte und Cut-offs unterschieden sich jedoch meist.
Fragestellung
Wie gut ist Serum-p-tau217 im Vergleich zu Plasma für die Diagnose von Alzheimer-Pathologie und den klinischen Nutzen?
Methode
Messung von p-tau217 in Plasma und Serum bei 100 Personen im Alzheimer-Kontinuum mit 6 Assays auf 4 Plattformen; Analyse von Korrelation, Passing-Bablok-Regression und ROC.
Ergebnisse
Für die meisten Assays bestanden hohe Plasma-Serum-Korrelationen (ρ > 0,8); Lumipulse zeigte fast perfekte Korrelation (ρ = 0,98). Plasma lieferte oft höhere Konzentrationen. Plasma-Cut-offs führten in Serum zu Fehlklassifikationen von 16 % bis 47 %; Lumipulse 10 % in Serum vs. 5 % in Plasma.
Einschränkungen
Nicht alle Assays schnitten im Serum gleich gut ab; die Validierungsleistung war unterschiedlich.
Schlussfolgerung der Autor:innen
Serum-p-tau217 zeigte über mehrere Plattformen starke Korrelationen mit Plasma und ähnliche Verläufe im Alzheimer-Kontinuum. Für die meisten Assays waren jedoch matrixspezifische Cut-offs nötig.
Kernaussagen
- Starke Plasma-Serum-Korrelationen für die meisten Assays
- Absolute Konzentrationen unterschieden sich meist zwischen den Matrizes
- Plasma-Cut-offs führten im Serum oft zu Fehlklassifikationen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 13.11.2025. Verfasst von Andrea L Benedet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sw…. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Gothenburg, Weston Brain Institute, CIHR.
Themen: Demenz
Abstract (Originalsprache)
Background
Phosphorylated tau 217 (p-tau217) has emerged as a leading blood-based biomarker for Alzheimer disease (AD). While typically measured in plasma, serum is a widely used matrix in clinical laboratories, yet few p-tau217 assays have been validated for serum. Evaluating serum p-tau217 performance is essential for expanding its use in clinical and research settings, particularly for cohorts with only serum samples available.
Methods
We quantified p-tau217 in plasma and serum from individuals within the AD continuum (n = 100; mean age 72.5 ± 5.0 years; 54% female) using 6 assays across 4 platforms. Spearman correlation, Passing–Bablok regression, and receiver operating characteristics analysis were used to assess intermatrix agreement and diagnostic performance. Specific validation parameters (e.g., precision, parallelism, dilution linearity, stability) were evaluated in both matrices.
Results
High correlations between plasma and serum were observed for most assays (ρ > 0.8), though plasma often yielded higher concentrations. Notably, the Lumipulse assay showed near-perfect correlation (ρ = 0.98) and minimal bias. Fold changes in p-tau217 levels across the AD continuum were comparable between matrices, though cutoffs for detecting AD pathology differed. Applying plasma-derived cutoffs to serum resulted in misclassification rates ranging from 16% to 47%, except for Lumipulse (10% in serum vs 5% in plasma). Not all assays performed equally in serum, as reflected in validation metrics.
Conclusions
Serum p-tau217, across multiple platforms, shows strong correlations with plasma p-tau217 and reflected comparable patterns across the AD continuum. However, absolute concentrations differed for most assays, thus requiring differing disease specific cutoffs. Most of the evaluated platforms demonstrated reliable quantification of p-tau217 in serum, yielding satisfactory validation performance. These findings support serum as a viable alternative to plasma for p-tau217 quantification in both research and clinical settings, provided matrix-specific validation is ensured.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
- Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
- Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated…
- School of Medicine and Public Health, Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, WI, United States.
ORCID-Profile: Burak Arslan, Hlin Kvartsberg, Henrik Zetterberg, Oskar Hansson
Förderung
- University of Gothenburg
- Weston Brain Institute
- CIHR
- Canadian Consortium of Neurodegeneration and Aging
- Brain Canada Foundation
- Fonds de Recherche du Québec-Santé
- Swedish Alzheimer Foundation
- Stiftelsen för Gamla Tjänarinnor
Zitieren
APA
Benedet, A. L., Arslan, B., Tan, K., Huber, H., Pola, I., Di Molfetta, G., Kvartsberg, H., Dolado, A. O., Janelidze, S., Blennow, K., Zetterberg, H., Hansson, O., Rosa-Neto, P., & Ashton, N. J. (2026). Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?. Clinical Chemistry, 72(2), 303-315. https://doi.org/10.1093/clinchem/hvaf162
Vancouver
Benedet AL, Arslan B, Tan K, Huber H, Pola I, Di Molfetta G, et al. Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?. Clinical Chemistry. 2026;72(2):303-315. doi:10.1093/clinchem/hvaf162
BibTeX
@article{Benedet2026,
author = {Benedet, Andrea L and Arslan, Burak and Tan, Kubra and Huber, Hanna and Pola, Ilaria and Di Molfetta, Guglielmo and Kvartsberg, Hlin and Dolado, Anna Orduña and Janelidze, Shorena and Blennow, Kaj and Zetterberg, Henrik and Hansson, Oskar and Rosa-Neto, Pedro and Ashton, Nicholas J},
title = {Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?},
journal = {Clinical Chemistry},
year = {2026},
volume = {72},
number = {2},
pages = {303--315},
doi = {10.1093/clinchem/hvaf162}
}
EUVIMED